Korro Bio reported a net loss of $17.5 million for the third quarter of 2026 as the company transitioned into a clinical-stage entity with the commencement of its Phase 1/2 ANCHOR trial. Collaboration revenue fell to zero during the period following a strategic pause in its agreement with Novo Nordisk, which has now been formally terminated for convenience effective February 2027.
Key Highlights
- Novo Nordisk issued a notice of termination for its 2024 cardiometabolic research collaboration and license agreement, which will be effective on February 1, 2027.
- Cash and marketable securities increased to $124.8 million as of September 30, 2026, which is projected to fund operations into the second half of 2028.
- Clinical development progressed with the initiation of dosing for healthy volunteers in the Phase 1/2 trial of KRRO-121, with an interim readout anticipated in the second half of 2027.